Week 5 Flashcards

1
Q

overviews of oncologic emergency categories

A

metabolic
*hypercalcemia of malignancy
*tumor lysis syndrome

hematologic
*febrile neutropenia

structureal
*spinal cord compression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Oncologic Emergency type

tumor lysis syndrome

Patho:

Clinical Presentation:

Risk factors:

Dx and workup:

Prevention:

Mgt/treatment plan:

A

Patho: occurs when large number of cancer cells die ithin a short period of time. cell contents are released into the blood. including dna, phosphate, potassium,-> leads to production of uric acid-> deposit in kidneys

Clinical Presentation:
Hyperkalemia (ecg abnomalities, cardiac arrest)
hypruricmemia(aki, crystal nephropathy)
hyperphosphatemia(ak, gi upset, ams)
hypocalcemia (ams, seizures, tetany)

Risk factors:
Cancer related: high proliferative, tumor bulk, circulating tumor cells, sensitivity to chemo
pt specific: elevated UA, nephropathy, hydration sttaus, hypotension, acidic uring, HF

Dx and workup:
lab TLS: >/2 or more of metabolic abnormalities w.in 3 days before or 7 days after initial trt.
*hyperkalemia>6
*hyperuricemia>8
hyperphosphatemia>4.5
*hypocalcemia</7
or 25% increase or decrease(calcium) from baseline

clinical tls: lab tls SS +
*aki
*seizures
*cardiac arrythmias

Prevention:
*hold causative agents
*hydration, avoid sodium bicarb

Mgt:

high risk: hydration, rasburicase, allopurinol
intermediate risk: hydration, allopurinol, consider rasburicase
low risk: observation, normal hydration, monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

mgt of TLS

allopurinol

moa:
indication:
dosing:
consideration:

A

mgt of TLS

allopurinol

moa: decreased formation of uric cid formation
indication: pt at risk for devloping tls. initiate 24 hrs before chemo
dosing: 300 mg po daily
consideration:
ddi
renal function
severe hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

mgt of TLS

rasburicase

moa:
indication:
dosing:
consideration:

A

mgt of TLS

moa: reduce uric acif levels, wont inhibit uric acid formation

indication:preexsiting hyperuricemia

dosing: 1.5 mg or 3 mg

consideration:
leave blood samples on ice. heat can break down uric acid een more. put sample on ice,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

refractory tls to rasburicase

A

use dialysis

rare

refractory volume overload, oligouria, and anuria

persistent hyperkalemia or hyperuricemia

hyperphosphatemia induced hypocalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

trt of hyperkalemia in tls

A

hydration- diuretics to optimize urine output

caclium chloride-stabilizes cardiac cell membrane

regular insulin: drives K intracellularly

sodium bicarb: drive K+ intracelularly by increasing ph

sodium polystyrene: promotes gi excretion of K

dialysis: removes K+ thorugh blood filtration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

trt of hyperphosphatemia

A

first line: hydration

lmit dietary phosphate to 800-1000 mg/day

phophate binders: calcium acetate, calcium cabronate, aluminum hydroxide, lanthanum, sevelamer

last line dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

trt of hypocalcemia

A

resolves w. resolution of hyperphosphatemia

only trt symptomatic hyperphosphatemia to avoid overcorrection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Oncologic Emergency type

febrile neutropenia

Patho:

Clinical Presentation:

Risk factors:

Dx and workup:

Prevention:

Mgt/treatment plan:

A

Oncologic Emergency type

fever: single temp >38.3 OR temp>38C for over 1 hour AND ANC<500 or ANC<1000 and expected to drop to <500 in 48hrs

*often first and osmetimes only sign an immunocompromised pt has developed an infection

Patho:

Clinical Presentation:

Risk factors:

Dx and workup:
Low: anticipated <7 days
ntermediate: anticipated 7-10 days
high neutropenia >10 days

hx and physical, labs (cbc, renal function tests, lfts, electrolytes, microbe culture

Prevention:
low risk: none
intermediate: consider bacterial, funcal . use viral
high risk: use bacterial, consider fungal, and use viral

Mgt/treatment plan:

antimicrobials: levofloxcin and ciprofloxacin

pneumoccal: penecillin vk

antifungal: floconazole, posaconazole, voriconazole, micafungin, caspofungin

pneumocystisis: bactrim

viral: acyclovir

csf: Pegfilgastrim, filgastrim

Risk assessmen score: MASCC score
*high risk: <21
low risk>/21

low risk: outpt mgt-> oral abx

high risk pt: inpt mgt. broad spectrum iv abx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

oral options for outpt management of febrile neutropenia

A

ciprofloxacin +augmentin

levofloxacin

moxifloxcain

ciprofloxacin +clindamycin

oraloptions not appropriate for pts on fluoro quinolones at time of diagnosis
pts w. N/V

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

in pt management of febrile neutropenia

A

iv therapy

monotherapy w. broad spectrum anti pseudamonal abx

cefepime
pip tazo
meropenem
imipenem
ceftazidime

double gram-coverage can be condisrd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

mrsa coverage in febrile neutropenia

A

not covered unless specific indicaion

ex; catheter related infections
ssti
pneumonia
mucositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

fungal coverage in febrile neutropenia

A

fungal coverage added later on in course of febrile neutropenia..

only add if have + fungal markers (beta d glucan..) positive fungal cultures, doesnt respond to initial therapy in 4-7 days

trt: fluconazole, voriconazole, itraconazole, isavuconazole, posaconazole, liposomal amphotericin b

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

duration of treatment for fbrile neutropenia

A

unidentified infection
*continue untik
**anc >500
and afebrile >/2 days

identified infection:
ssti 7-14 days
blood stream infction: Gram-, 10-14 days: gram+ 7-14 days
bacterial sinusitis:7-14 days
bacterial pneumonia: 7-14 days
fungal (candida=2 weeks: mold=12 weeks)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Oncologic Emergency type

hypercalcemia of malignancy

Patho:

Clinical Presentation:

Risk factors:

Dx and workup:

Prevention:

Mgt/treatment plan:

A

Oncologic Emergency type

Patho:
humoral hypercalcemia: mediated by systemic secretion of PTH hormone. 80% of all cases

osteolytic hypercalcemia: increase osteoclastic bone resorption

vitamin d secreting lymphoma

ectopic hyperparathyoidism<1% cases

Clinical Presentation:
mild hypercalcemia: corrcted calcium
neurologic lethargy, confusion, irratibility, muscle weakness, etc.

Risk factors:

Dx and workup:

Prevention:

Mgt/treatment plan:
symptomatic hypercalcemia is an oncologic emergency
primary goal: treat underlying malignancy

hold medicines that can potentially worsen hypercalcemia

  1. HYDRATION: saline +/- furosemide (increase calciuresis)

primary therapies: iv biphosphonates, rank-l inhibitors

secondary therapies: calcitonin, glucocorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

biphosphonates

A

agents: zolendreic acid
pamidronate

inhibt bone resorption

takes up to 7-days to see effects

AE:!! flu like symptoms (pppx w. tylenol)!!, fevers arthralgias , neohrotoxicity,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

denosumab

A

rank-l inhibitor reduce osteoclast acitivity

efficacy: 9-10 days

used in hyprcalcemia refractory to biphosphonates. use in pts w.evere renal impairment

toxicity: severe hypocalcemia, hypophosphatemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

calcitonin

A

inhibits bone resportion

can cause tachyphylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

other agents for hypercalcemia of malignancy

A

glucocorticoids: inhibits osteoclastic bone resoprtin by decreasing cytokines:

calcimemmetics (cinacalcet: effective for PTH carcinoma or primary/secondary hyperparathyroididm

dialysis: severe hypercalcemia due to renal insufficiency
*unable to hydrate pt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

forms of lung cancer

A

2 forms of lung cancer

Non small cel85%) cmall cell(15%
Non small cell
*squamous (30) *non squamous70%)

Nonsquamous (
a)large cell (10%)
b)adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

clinical presentation of lung cancer

A

Clinical presentation of lung cancer
*pulmonary symptoms: cough dyspnea, chest pain or disocmfort, w. Or w.o hemoptysis
Extrapullmonary: fatigue, weightloss, anorexia

Paraneoplastic syndromes: hypercalcemia and siadh

disseminated disease can cause additional symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

most effective prevention in lung cancer

A

Most efective prevention in lung cancer:
*avoid tobacco
*maintain healthy diet high in fruits and vegetables
*offer screening to high risk individuals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

general treatment goals for NSCLC

A

Treatment goals for NSCLC
*stage 1-11: cure
Stage III-Iv: prolongation of survival

Treatment goals for SCLC
Limited stage: cure
Extensive stage: prolongation of survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

local NSCLC (stage 1-2) trt

A

Stage 1:curgery
Stage 2:
Surgery followed by adjuvant therapy
Platinum based chemo regimen for 4 cycles
Osimertinib (EGFR+) for up to 3 years
Atezolizumab (PD-L1>/1%)
Neoadjuvant (therapy b4 surgery to shrink tumor down to increase chances of complete tumor removal
Radiation therapy
Reserved for pts who cant get surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

local advanced stage nsclc (stage 3 tretment

A

Local advanced stage NSCLC (stage3) treatment
Stage 3a
Neoadjuvant chemo+/-nivolimumab
Adjuvant osimertinib (EGFR+) OR atezolizumab (PDL1>/1%)
Concurrent chemoradiotherapy for non surgical candidates
Stage 3b-3c
Considered unresectable disease
Concurrent chemo radiaion
Immunotherapy to increase progression free and overall survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

neoadjuvant regimens for nsclc

A

Neoadjuvant regimens for nsclc
Cisplatin or carboplatin incombo w. Other agents that are non platinum agents
*** pemetrexid only for nonsquamous histology only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

cisplatn vs carboplatin

A

Cisplatin
Myelosupression
n/v
Diarrhea constipation
Oral mucosisitis
Alopecia
Nephrotoxicity (hypokalemia, hypomagnesemia)
Ototoxicity
Peripheral neuropathy

Carboplatin
Thrombocytopenia
Less n/v than cisplatin
diarrhea/ constipation
Oral mucositis
Alopecia
nephrotox(less than cisplatin)
Ototoxicity (less than cisplatin
Peripheral neuropathy (less than cisplatin)
Calvert equation: equation used to determine n dosing carboplatin based on pt renal function. Reduced risk of toxicities that we cant do w. Cisplatin

28
Q

cisplatin equation

A

Total dose= AUCX(CRcL+25)

29
Q

advanced nsclc stage 4 or relapsed trt

A

Advances nsclc: stave 4 or relapsed disease trt
If pt has targeted genetic mutation
Mutation in any: EGFR, ALK, ROS1,BRAF NTRK, RET, MET
Kinase inhibitor targeted to mutation
PDL1+>/50%
pd1/pdl1inhibitor+/-chemo
pdl1<1
Pdl1 inhibitor + chemo

30
Q

advanced nsclc trt

EGFR inhibitors in nsclc

A

growth factor receptor inhibitors
Egfr mutations most prevalent in adenocarcinomas and non smokers
Agent examples
First (Erlotinib, gefitinib, afatinib
Second gen: (dacomitinib
Third: osimertinib FIRST LINEEE!!
Significantly improved PFS and os CAPERED TO FIRST GEN AGENTS, AND IMPROVED CNS ACTIVITY, BETTER TOLERABILITY

31
Q

EGFR inhibitor AE

A

EGFR INHIBITOR AE:
Class adverse effects
Skin rash
Dry skin
Nail toxicity
Diarrhea
conjunctivitis
SPECIFIC drug side effects
Osimertinib
Cyp3a4 substrate
No ph dependent absorption
Myelosupression
Dose reduction for severe renal impairment

32
Q

advanced nsclc trt

alk inhibitors

A

ALK INHIBITORS
Less common than egfr mutations
Seocnd and third gen superior improvement in outcomes
First gen: crizotinib, certinib,
Second gen: alectinib, brigatinib
Third gen: lorlatinib

33
Q

advanced nsclc trt

alk inhibitor agent pearls

A

Brigatinib
Ddi: cyp3a4 substrate
Ph dependent absorption: no
AE: insterital lung disease/pneumonitis, myalgia, htn
Alectinib
Ddi: cyp3a4 substrate
Ph dependent absorption: no
AE: constipation, myalgias, lft elevation, anemias
Lorlatinib
Ddi: cyp3a4
Ph dependent absorption:
AE: depression, anxiety, has good cns penetration, weight increase

34
Q

advanced nsclc trt

KRAS inhibiots

A

More common mutation sthat smoke cigarrettes
Pts with this have poor disease prognosis
Indicated for nsclc and kras g12c mutation after recepit of one therpay

35
Q

advanced nsclc trt

kras inhibitor agent pearls

A

Sotorasinib
Ddi:cyp3a4 substrate
Ph dependent absorption:YES. Avoid ppis h2ra
AE:
Adagrasib
Ddi:
Ph dependent absorption: NONE
AE: renal impairment, qtc prolongation,

36
Q

advanced nsclc trt

agents if pdl1 expression >50%

A

PDL1 expression level of >/50% or higher TReatments
Single agent immunotherapy
Pembrolizumab
Atezolizumab
Cemiplimab

37
Q

advanced nsclc trt

pdl1 1-49%

A

PDL1 1-49%(BASICALLY MODERATE -low EXPRESSION)
Cisplatin or carpo +paclitaxel +permbrolizumab (squamous)
Cis or carb+ pemetrexed +pembrolizumab (non squamous)
Cis or carb +paclitaxel + nivolimumab
Etc.

38
Q

advanced nsclc trt

2nd line trt

A

No previous checkpoint inhibitor: pembrolizumab, nivolumab, atezolizumab
Previous checkpoint inhibitor: docetaxel+ramucirumab(preffered over single agent), ramurcirumab +pembrolizumab, docetaxel, pemetrexed

39
Q

immunothwrapy for nsclc patho

A

Immunotherapy for nsclc patho
Pd1l1: inhibits t cel killing of tumor cell-blocking allowst cell tumor killing
Ctla4: binding inhibits t cell acitivation: blocking potentiates t cell activation and killing

40
Q

advanced nsclc trt

immunotherapy AE

A

Immunotherapy related side effects in nsclc
Onst: w.in first few weks to months after initiation but can occur anytime
Combing bdl1/ctla4 increases side effects
Different grades of AE
Grade1:continue immunotherapy
Grade 2: hold immunotherapy and consider admin prednisone
gradde3>: hold immunotherapy and give prednisone (or equiv)
Pred: 0.5-2mg/kg/day 5-7 days
Steroid refractory: mycophenolate, infliximab

41
Q

advanced nsclc trt

VEGF inhibitors

A

VASCULAR ENDOTHELIAL GROWTH FACORS (VEGF)
Cancer cells form new blood cells, which increase nutrient flow and permit growth and metastasis
VEG F inhibitors
Nsclc specific agents: bevacizumab, ramucirumab
AE: HTN, thromboembolic events, major bleeds
Avoid in pts w, squamous histology (bevacizumab), recent hemoptysis, on tpx anticoagulation for new onset vte, recent surgical procedure.

42
Q

chemo for lung cancer

A

Taxanes
Nsclc specific agents: paclitaxel, docetaxel
Moa: inhibits mitosis
AE: myelosupression, ALOPECIA, PERIPHERAL NEUROPATHY(dose limiting ae), hypersensitivity (premdicate to prevent), peripheral edema (docetaxel

Pemetrexed
Moa: inhibits DHFR. inhibit folate synthesis, causing cell death
Ci: severe renal dysfunction (crcl<45), NSAIDS decrease clearance
AE: dose limiting (myelosupression, skin rashes)

43
Q

SCLC overview

A

Rapidly diving malignancy.
60-70% extensive disease stage
Poor prognosis
Trt of choice is chemo +/- radiation

44
Q

SCLC trt first line and second line

A

Sclc treatment
First line
Platinum agents +/- other agents
Cisplatin+etoposide
Carboplatin+etoposide
Carbo+epot+atezolizumab (extensive only)
Carbo+epot+durvulomab (extensive only)

Second line
Topetecan
Lurbinectedin
Clinical trial

45
Q

sclc trt agent pearls

A

Etoposide:
Moa: topoisomerase inhibitor
Dose limiting AE: myelosupression

Topotecan
Topoisomeras I inhibitor
Renal dosage adjustment
Myelosupression (neutropenia

Lurbinectedin
Moa: alkynates dna
Pk: cyp3a4 substrate
Fatigue, hepatic enzyme, extravasation, nausea

46
Q

what is lymphoma

A

What is it
Cancers of the lymphoid lineage
Low incidence
global

Two major divisions
Hodkins
Non hodgekins
*Can either be bcell, t-cell, or nk cell
*Also classified as
Indolent
Aggressive
Very aggressive

47
Q

mechanism of lymphomas

A

Mechanisms of infectious disease on causing l ymphomas : lymphocyte transforming viruses disrupt cell actiivty.

48
Q

types of lymphona

A

TYpes of Lymphoma
B cell nhl
T cell/nk NHL
HL

all divided up further into indolent, agressive, or very aggressive

49
Q

SS lymphadenoma

A

SS of lymphoma
Ymphadenoma
“B symptoms”
Fevers
Night sweats
Weight loss
Usually advanced disease

50
Q

diffuse large b cell lymphoma
overview

A

Diffuse Large B-CELL lymphoma (DLBCL)
Most common heme malignancy in usa
Germinal center bcl vs activator center b cell
Gcb has greater survival than ABC
40% of pts w. Adverse cytogenetics will experience failure (not all inclusive)

51
Q

prognosis of dlbcl

A

Prognosis of dlbcl
Best response to therapy: adherence of drug at specific dose
Anthracyclines are most impotant drugs (doxorubicine)
Fitness test
Who can fail?
AGE>60
STAGEIII-IV
ecog>2 (performance status … poorer activity)
LDH>UNL

52
Q

trt for dlbcl

A

GOLD STANDARD FOR DLBCL
R-CHOP
R: rituxumab on day 0
C:Cyclophosphamide on day 1
H: Doxorubicin on day 1
O: vincristine on day 1
P: prednisone
Given q21 days for usually 6 days

53
Q

trt of dlcbl

rituxumab

A

Rituxumab
Moa: mAb binds to CD20***
Increased OS by 15% when added to chop
Ae:
TLS
HOLD first cycle if tls risk is high
Infusino reactions, gi perforation, decrease efficacy of vaccines
Pearls: infusion directions, tls, hold if disease in gi tract

54
Q

trt of dlbcl

cyclophosphamide

A

Cyclophosphamide pearls
Alopecia
High NV risk
Hemmorhagic cystitis/fluids

55
Q

trt of dlbcl

doxorubicin

A

Doxorubicin pearls
Lifetime dose cap 450 mg/m2
Baseline ECHO due to nonreversible HF
Nv and mucositis

56
Q

trt of dlbcl

vincristine

A

Vincristine pearls
Neuropathy (NO VINES IN SPINE)
Neuropathy in sensory (taste, smell, touch)

57
Q

trt of dlbcl

prednisone

A

Prednisone pearls
Hyperglycemia
Steroid induced psychoses
Insomnia

58
Q

trt od dlbcl

CHOP supportive care

A

Chop supportive care
Emetic risk high
Antiemetics
Febrile neutropenia
Pegfilgastrim and filgastrim
Viral reactivation (ritxumab)
Give ppx antiviral for pts who have had hbv
Tls
Aggressive hydration
Allopurinol
Hold rituxumab?

59
Q

otions for pts w. poor lvef

A

Options for pts with poor lvef
Rceop
R-cepp
RCDOP
RGCVP
R-DA-EPOCH

60
Q

alternative therapy for RCHOP

A

Alternative for RCHOP (new therapy)
Pola-R-CHP
Add polatuzumab, remove vincristine
PGS improved
Acts similarly to vincristine

61
Q

DA-R-EPOCH

A

DA-R-EPOCH
Preferred over rchop in certain settings
duble/tripple hit lymphoma
Primarymediastinal lymphoma
Hiv associated dlbcl

62
Q

relapsed/refracctory dlbcl

A

Relapsed /refractory disease
Auto transplant
Definitive cure in second line
Giving stem cells back after taking them and purifying them.
High dose chemo given to prior to overcome resistance
CAR T-CELL
Definitive cur in second line
T cells flagged w. Anti cd19 antibodies (found on lymphomas)
AE: cytokine release syndrome, neurotoxiciy
Very well response rate
Palliation
Use other moa therapies

63
Q

follicular lymphoma

A

Follicular lymphoma(FL)
Indolent lymphoma
Rarely cured
Drugs work less
Indications fo treatment
Cytopenias
Consider grade, FLIPI score
Infections
Symptomatic disease
End organ function
Bulky disease
Change in aggressiveness diseas

First line trt of follicular lymphoma considerations
Obinutuzumab c rituxumab
Improves PFS
Infusion reactions
Rituxumab maintenance
BR v RCHOP

Relapsed refractory FL
Rule out transformation into DLBCL
DONT REPEAT SIMILAR REGIMENS
3RD LINE
Mosenutuzumab
Engaged cd3 t cells
AE: cytokine release syndrome
Complete response rate: 60%

64
Q

hodgekins lymphoma overview

A

Hodgekins Lymphoma
B cell lymphoma arising from germinal center
Highly curable
Divided into 2 categories
Classical hodgkins lymphoma (cHL)
CD20 NEG, CD30+
Nodular lymphocyte-predominant hodgkins lymphoma(NLPHL)
Cd20 +, cd30 -
Main risk factors
Epstein barr virus
HIV
Patho of HL
CHL do not express traditional b cell markers (ex!!! Substitute CD30)
Very inflammatory cancer; a lot of pro inflammatory markers

65
Q

NLPHL TRT

A

NLPHL TRT
CD20+ cd30-
RITUXUMAB + any chemo regimens
Classical HL TRT
ABVD
ADRIAMYCIN
BLEOMYCIN
VINBLATINE
DACARBAZINE
Pulmonary fibrosis
Infertility
Avoid in pulmonary function issues at baseline

AFTER 2 CYCLES, DO PET SCAN.
If refractory-> escalate to BEACOPP
If responsive, can remove bleomycin, to make AVD
Due to creation of free radicals, can cause pulmonary fibrosis, higher risk when given w. G-CSF (filgastrim and pegfilgrastim

Brentuximab
antiCD30
Side effects: neuropathathy
AAVD
Useful in some pts
High rates of neutropenia and neuropathy
Relapsed disease
Use different agent